The clinical management of familial cancer begins with recognition of patterns of cancer occurrence suggestive of genetic susceptibility in a proband or pedigree, to enable subsequent investigation of the underlying DNA mutations. In this regard, next-generation sequencing of DNA continues to transform cancer diagnostics, by enabling screening for cancer-susceptibility genes in the context of known and emerging familial cancer syndromes. Increasingly, not only are candidate cancer genes sequenced, but also entire 'healthy' genomes are mapped in children with cancer and their family members. Although large-scale genomic analysis is considered intrinsic to the success of cancer research and discovery, a number of accompanying ethical and technical issues must be addressed before this approach can be adopted widely in personalized therapy. In this Perspectives article, we describe our views on how the emergence of new sequencing technologies and cancer surveillance strategies is altering the framework for the clinical management of hereditary cancer. Genetic counselling and disclosure issues are discussed, and strategies for approaching ethical dilemmas are proposed.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Meyerson, M., Gabriel, S. & Getz, G. Advances in understanding cancer genomes through second-generation sequencing. Nat. Rev. Genet. 11, 685–696 (2010).
Schiffman, J. D. et al. Update on pediatric cancer predisposition syndromes. Pediatr. Blood Cancer 60, 1247–1252 (2013).
Bakry, D. et al. Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium. Eur. J. Cancer 50, 987–996 (2014).
Vasen, H. F. et al. Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium “Care for CMMR-D” (C4CMMR-D). J. Med. Genet. 51, 283–293 (2014).
Hill, D. A. et al. DICER1 mutations in familial pleuropulmonary blastoma. Science 325, 965 (2009).
Choong, C. S., Priest, J. R. & Foulkes, W. D. Exploring the endocrine manifestations of DICER1 mutations. Trends Mol. Med. 18, 503–505 (2012).
de Kock, L. et al. Germ-line and somatic DICER1 mutations in pineoblastoma. Acta Neuropathol. 128, 583–595 (2014).
Rothenberg, S. M. & Settleman, J. Discovering tumor suppressor genes through genome wide copy number analysis. Curr. Genomics 5, 297–310 (2010).
Costa, J. L., Meijer, G., Ylstra, B. & Caldas, C. Array comparative genomic hybridization copy number profiling: a new tool for translational research in solid malignancies. Semin. Radiat. Oncol. 18, 98–104 (2008).
Comino-Mendez, I. et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat. Genet. 43, 663–667 (2011).
Smith, M. J. et al. Loss of function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nat. Genet. 45, 295–298 (2013).
Shah, S. et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat. Genet. 45, 1226–1231 (2013).
Stadler, Z. K., Schrader, K. A., Vijai, J., Robson, M. E. & Offit, K. Cancer genomics and inherited risk. J. Clin. Oncol. 32, 687–698 (2014).
Baylin, S. B. & Jones, P. A. A decade of exploring the cancer epigenome—biological and translational implications. Nat. Rev. Cancer 11, 726–734 (2011).
Lawlor, E. R. & Theiele, C. J. Epigenetic changes in pediatric solid tumors: promising new targets. Clin. Cancer Res. 18, 2768–2779 (2012).
Killian, J. K. et al. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov. 3, 648–657 (2013).
Choufani, S., Shuman, C. & Weksberg, R. Molecular findings in Beckwith–Wiedemann syndrome. Am. J. Med. Genet. C. Sem. Med. Genet. 163C, 131–140 (2013).
Mardis, E. R. Next-generation sequencing platforms. Annu. Rev. Anal. Chem. (Palo Alto Calif.) 6, 287–303 (2013).
Idris, S. F., Ahmad, S. S., Scott, M. A., Vassiliou, G. S. & Hadfield, J. The role of high-throughput technologies in clinical cancer genomics. Expert Rev. Mol. Diagn. 13, 167–181 (2013).
Rahman, N. Realizing the promise of cancer predisposition genes. Nature 505, 302–308 (2014).
Meijers-Heijboer, H. et al. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat. Genet. 31, 55–59 (2002).
Hu, H. et al. A unified test of linkage analysis and rare variant association for analysis of pedigree sequence data. Nat. Biotechnol. 32, 663–669 (2014).
Gartner, J. J. et al. Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc. Natl Acad. Sci. USA 110, 13481–13486 (2013).
Ward, L. D. & Kellis, M. Interpreting noncoding genetic variation in complex human traits and human disease. Nat. Biotechnol. 30, 1095–1106 (2012).
Turnbull, C. et al. Gene–gene interactions in breast cancer susceptibility. Hum. Mol. Genet. 21, 958–962 (2012).
Moorman, P. G. et al. Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. Breast Cancer Res. Treat. 124, 441–451 (2010).
Samuel, N. & Hudson, T. J. Translating genomics to the clinic: implications of cancer heterogeneity. Clin. Chem. 59, 127–137 (2013).
Zhuang, Z. et al. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N. Engl. J. Med. 367, 922–930 (2012).
Scott, R. H. et al. Stratification of Wilms tumor by genetic and epigenetic analysis. Oncotarget 3, 327–335 (2012).
Behjati, S. et al. A pathogenic mosaic TP53 mutation in two germ layers detected by next generation sequencing. PLoS ONE 9, e96531 (2014).
Stein, L. D. An introduction to the informatics of “next-generation” sequencing. Curr. Protoc. Bioinformatics 11, 11.1 (2011).
Biesecker, L. G., Burke, W., Kohane, I., Plon, S. E. & Zimmern, R. Next-generation sequencing in the clinic: are we ready? Nat. Rev. Genet. 13, 818–824 (2012).
Knapke, S., Nagarajan, R., Correll, J., Kent, D. & Burns, K. Hereditary cancer risk assessment in a pediatric oncology follow-up clinic. Pediatr. Blood Cancer 58, 85–89 (2012).
Fernandez, C. V. et al. Attitudes of parents to the return of targeted and incidental genomic research findings in children. Genet. Med. 16, 633–640 (2014).
Ross, L. F., Saal, H. M., David, K. L., Anderson, R. R. & American Academy of Pediatrics; American College of Medical Genetics and Genomics. Technical report: ethical and policy issues in genetic testing and screening of children. Genet. Med. 15, 234–245 (2013).
Fabsitz, R. B. et al. Ethical and practical guidelines for reporting genetic research results to study participants: updated guidelines from a National Heart, Lung, and Blood Institute working group. Circ. Cardiovasc. Genet. 3, 574–580 (2010).
Wolf, S. M. Return of individual research results and incidental findings: facing the challenges of translational science. Annu. Rev. Genomics Hum. Genet. 14, 557–577 (2013).
Green, R. C. et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 15, 565–574 (2013).
American College of Medical Genetics and Genomics. ACMG Updates Recommendation on “Opt Out” for Genome Sequencing Return of Results [online], (2014).
McGuire, A. L. et al. Point–counterpoint. Ethics and genomic incidental findings. Science 340, 1047–1048 (2013).
Holm, I. A. et al. Guidelines for return of research results from pediatric genomic studies: deliberations of the Boston Children's Hospital Gene Partnership Informed Cohort Oversight Board. Genet. Med. 16, 547–552 (2014).
Clayton, E. W. et al. Addressing the ethical challenges in genetic testing and sequencing of children. Am. J. Bioeth. 14, 3–9 (2014).
Eckstein, L., Garrett, J. R. & Berkman, B. E. A framework for analyzing the ethics of disclosing genetic research findings. J. Law Med. Ethics 42, 190–207 (2014).
Fernandez, C. V. et al. Attitudes of Canadian researchers toward the return to participants of incidental and targeted genomic findings obtained in a pediatric research setting. Genet. Med. 15, 2558–2564 (2013).
Rasmussen, A. et al. Uptake of genetic testing and long-term surveillance in von Hippel–Lindau disease. BMC Med. Genet. 11, 4 (2010).
Barrow, P., Khan, M., Lalloo, F., Evans, D. G. & Hill, J. Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome. Br. J. Surg. 100, 1719–1731 (2013).
Brandi, M. L. et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 86, 5658–5671 (2001).
Ramirez-Ortiz, M. A. et al. Diagnostic delay and sociodemographic predictors of stage at diagnosis and mortality in unilateral and bilateral retinoblastoma. Cancer Epidemiol. Biomarkers Prev. 23, 784–792 (2014).
Green, D. The evolution of treatment of Wilms tumor. J. Pediatr. Surg. 48, 14–19 (2013).
Ward, E., DeSantis, C., Robbins, A., Kohler, B. & Jemal, A. Childhood and adolescent cancer statistics, 2014. CA Cancer J. Clin. 64, 83–103 (2014).
Villani, A. et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li–Fraumeni syndrome: a prospective observational study. Lancet Oncol. 12, 559–567 (2011).
Broniscer, A. et al. Clinial and molecular characteristics of malignant transformation of low-grade glioma in children. J. Clin. Oncol. 25, 682–689 (2007).
Jasperson, K. W. et al. Role of rapid sequence whole-body MRI screening in SDH-associated hereditary paraganglioma families. Fam. Cancer 13, 257–265 (2014).
Choyke, P. L., Siegel, M. J., Craft, A. W., Green, D. M. & DeBaun, M. R. Screening for Wilms tumor in children with Beckwith–Wiedemann syndrome or idiopathic hemihypertrophy. Med. Pediatr. Oncol. 32, 196–200 (1999).
Lammens, C. R. et al. Regular surveillance for Li–Fraumeni syndrome: advice, adherence and perceived benefits. Fam. Cancer 9, 647–654 (2010).
Rothschild, P. R. et al. Familial retinoblastoma: fundus screening schedule impact and guideline proposal. A retrospective study. Eye (Lond.) 25, 1555–1561 (2011).
Canadian Retinoblastoma Society. National Retinoblastoma Strategy Canadian Guidelines for Care: stratégie thérapeutique du rétinoblastome guide clinique canadien. Can. J. Ophthalmol. 44 (Suppl. 2), S1–S88 (2009).
Imhof, S. M., Moll, A. C., Schouten-van Meeteren, A. Y. Stage of presentation and visual outcome of patients screened for familial retinoblastoma: nationwide registration in the Netherlands. Br. J. Ophthalmol. 90, 875–878 (2006).
Cairns, S. R. et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 59, 666–689 (2010).
Tan, T. Y. & Amor, D. J. Tumour surveillance in Beckwith–Wiedemann syndrome and hemihyperplasia: a critical review of the evidence and suggested guidelines for local practice. J. Paediatr. Child Health 42, 486–490 (2006).
McNeil, D. E., Brown, M., Ching, A. & DeBaun, M. R. Screening for Wilms tumor and hepatoblastoma in children with Beckwith–Wiedemann syndromes: a cost-effective model. Med. Pediatr. Oncol. 37, 349–356 (2001).
Clericuzio, C. L. et al. Serum alpha-fetoprotein screening for hepatoblastoma in children with Beckwith–Wiedemann syndrome or isolated hemihyperplasia. J. Pediatr. 143, 270–272 (2003).
Poulsen, M. L., Budtz-Jørgensen, E. & Bisgaard, M. L. Surveillance in von Hippel–Lindau disease (vHL). Clin. Genet. 77, 49–59 (2010).
Listernick, R., Ferner, R. E., Liu, G. T. & Gutmann, D. H. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann. Neurol. 61, 189–198 (2007).
Bree, A. F., Shah, M. R. & BCNS Colloquium Group. Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS). Am. J. Med. Genet. A 155A, 2091–2097 (2011).
Evans, D. G. et al. Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br. J. Neurosurg. 19, 5–12 (2005).
Krueger, D. A., Northrup, H. & International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr. Neurol. 49, 255–265 (2013).
Geller, J. I., Leslie, N. D. & Yin, H. Malignant Rhabdoid Tumor Follow-up [online], (2012).
Schultz, K. A. et al. Judicious DICER1 testing and surveillance imaging facilitates early diagnosis and cure of pleuropulmonary blastoma. Pediatr. Blood Cancer 61, 1695–1697 (2014).
Doros, L. et al. DICER1-realted disorders (eds Pagon, R. A. et al.) in GeneReviews® [internet] (University of Washington; 2014).
The work of the authors is supported in part by grants from the Canadian Institutes of Health Research (CIHR) to D.M. Both N.S. and A.V. receive salary support through scholarships from CIHR.
The authors declare no competing financial interests.
About this article
Cite this article
Samuel, N., Villani, A., Fernandez, C. et al. Management of familial cancer: sequencing, surveillance and society. Nat Rev Clin Oncol 11, 723–731 (2014). https://doi.org/10.1038/nrclinonc.2014.169
Drug Discovery Today (2021)
Genome Medicine (2019)
European Journal of Pediatrics (2018)
The PiGeOn project: protocol of a longitudinal study examining psychosocial and ethical issues and outcomes in germline genomic sequencing for cancer
BMC Cancer (2018)
Targeted Sequencing of Malignant Supratentorial Pediatric Brain Tumors Demonstrates a High Frequency of Clinically Relevant Mutations
Pediatric and Developmental Pathology (2018)